Literature DB >> 20424627

Anemia: To TREAT or not to TREAT--that is the question.

Andrzej Wiecek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20424627     DOI： 10.1038/nrneph.2010.35

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

Authors:  Deborah L Regidor; Joel D Kopple; Csaba P Kovesdy; Ryan D Kilpatrick; Charles J McAllister; Jason Aronovitz; Sander Greenland; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

2.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

Review 3.  Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.

Authors:  G F M Strippoli; S D Navaneethan; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

4.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.

Authors:  Patrick S Parfrey; Robert N Foley; Barbara H Wittreich; Daniel J Sullivan; Martin J Zagari; Dieter Frei
Journal:  J Am Soc Nephrol       Date:  2005-05-18       Impact factor: 10.121

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.

Authors:  Allan J Collins; Suying Li; Wendy St Peter; Jim Ebben; Tricia Roberts; Jennie Z Ma; Willard Manning
Journal:  J Am Soc Nephrol       Date:  2001-11       Impact factor: 10.121

7.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

8.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

9.  Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesco Locatelli; Ronald L Pisoni; Christian Combe; Juergen Bommer; Vittorio E Andreucci; Luis Piera; Roger Greenwood; Harold I Feldman; Friedrich K Port; Philip J Held
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

10.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.